You are here

  • Home
  • Archive
  • Volume 73, Issue 5
  • Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials

Citation Tools

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Strand V, Levy RA, Cervera R, et al
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials
Annals of the Rheumatic Diseases 2014;73:838-844.